Noida based pharmaceutical company, Jubilant Life Sciences revealed that it has joined hands with a US-based research institute to develop new drugs in order to combat tuberculosis in the subcontinent.
The company said that its US subsidiary, Chemsys, will be collaborating with Infectious Disease Research Institute (IDRI) in developing a new TB drug. IDRI has received over $3.4 million grant from the Bill and Melinda Gates Foundation as part of the Lilly TB drug discovery initiative (LTI) which has led to the generation of hundreds of novel chemical entities, including those that can be used for further exploration in developing new drugs.
Jubilant drug discovery services president Subir Basak said that his company will be providing 'support and expertise in synthesis of chemical entities for early research in TB.'
Stating that the collaboration will push them closer towards developing new drugs for TB, IDRI's vice president of drug discovery Dr Tanya Parish said, "We have been impressed with the commitment and engagement from Jubilant Chemsys in support of TB drug discovery over the past few years. We are excited to expand our efforts with them to access additional synthetic and medicinal chemistry capabilities. This will take us another step closer to our goal of developing much-needed new drugs to combat tuberculosis."